Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 60 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

8%

4 of 50 completed with results

Key Signals

4 with results100% success

Data Visualizations

Phase Distribution

60Total
Not Applicable (4)
P 1 (55)
P 2 (1)

Trial Status

Completed50
Unknown7
Active Not Recruiting2
Withdrawn1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 50 completed trials

Clinical Trials (60)

Showing 20 of 20 trials
NCT07367958Phase 1Active Not RecruitingPrimary

A Study to Compare the Auto-injector and Pre-filled Syringe of CT-P52 in Healthy Male Subjects

NCT07340476Phase 1Active Not RecruitingPrimary

A Study to Evaluate the PK Similarity of AK112 in Healthy Chinese Male Subjects

NCT06951828Phase 1CompletedPrimary

A Study to Compare the Auto-injector and Pre-filled Syringe of CT-P43 in Healthy Male Subjects

NCT05245669Phase 1CompletedPrimary

Study to Compare the Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Immunogenicity of Biosimilar Denosumab With Prolia® in Healthy Adult Male Volunteers

NCT07054970Phase 1CompletedPrimary

To Compare the Pharmacokinetics, Safety and Immunogenicity of CT-P55 and Cosentyx in Healthy Subjects

NCT03931590Phase 1CompletedPrimary

A Human AME Study for Omaveloxolone

NCT06837142Phase 1CompletedPrimary

A Drug-drug Interaction Study With TS-172 in Healthy Adult Male Subjects

NCT06596356Phase 1CompletedPrimary

A Mass Balance Study of TS-172 in Healthy Adult Subjects

NCT04814771Phase 1CompletedPrimary

Mass Balance Study of TS-142 in Healthy Adult Subjects.

NCT06472531Phase 1CompletedPrimary

A Study of PET/CT Imaging Using INR101 Injection in Healthy Male Subjects and Patients With Suspected Prostate Cancer

NCT06111196Phase 1CompletedPrimary

Compare the Pharmacokinetics and Safety of BAT3306 Injection Versus KEYTRUDA® Administered in Healthy Male Subjects

NCT05275010Phase 1CompletedPrimary

A Study in Healthy Male Subjects to Investigate the Comparability of Pharmacokinetics of the Fixed-Dose Combination of Pertuzumab and Trastuzumab Administered Subcutaneously Using a Handheld Syringe or Using the On-Body Delivery System

NCT05126784Phase 1CompletedPrimary

AVT03 With Prolia in Healthy Male Subjects

NCT05559554Phase 1CompletedPrimary

A Study to Evaluate the PK Similarity of AK104 in Healthy Chinese Male Subjects

NCT04147910Phase 1CompletedPrimary

Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-KW-6356

NCT05998304Phase 1CompletedPrimary

ADME Study of [14C] Yiqibuvir in Healthy Male Subjects

NCT06087978Phase 1CompletedPrimary

Study of RPT193 in Healthy Adult Male Subjects

NCT05792917Phase 1CompletedPrimary

Bioequivalence Study of Tafolecimab Injections in Chinese Healthy Male Volunteers

NCT05888207Phase 1CompletedPrimary

A Study to Assess the Effects of Fluvoxamine on Savolitinib Exposure in Healthy Male Subjects

NCT05337267Phase 1CompletedPrimary

Phase I Study of Sintilimab in Healthy Chinese Male Subjects

Scroll to load more

Research Network

Activity Timeline